
Publicaties op basis van Nederlandse RWE veiligheids- en effectiviteitsdata in de behandeling van atopisch eczeem
Deze website is uitsluitend voorbehouden aan beroepsbeoefenaren in Nederland.
Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.
Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening blood disorder characterized by severe deficiency of the enzyme ADAMTS13, leading to the formation of microthrombi in small blood vessels. This condition requires prompt and effective treatment to prevent serious complications. Caplacizumab is an innovative nanobody® and cornerstone in the treatment of iTTP.1 This article delves into real-world data from Belgian hospitals on the use of caplacizumab, highlighting its efficacy, safety, and impact on patient outcomes.2
Op deze pagina vindt u de meest recente internationale en nationale richtlijnen voor de diagnose en behandeling van atopisch eczeem. Deze richtlijnen zijn opgesteld door vooraanstaande medische organisaties en bieden artsen wetenschappelijk onderbouwde aanbevelingen voor een effectieve en verantwoorde behandeling van patiënten met atopisch eczeem. De richtlijnen omvatten advies over diagnostische criteria, behandelopties zoals topische en systemische therapieën, en het belang van patiëntgerichte zorg.
This infographic summarizes survey data* about the impact that families in the Netherlands and Belgium have felt when being diagnosed with autoimmune Type 1 Diabetes (T1D).
Systematic early detection of autoimmune Type 1 Diabetes might be a new way to avoid acute and chronic complications of the condition.1-5 This new approach may play a role as a revolutionary shift, helping to shape the future of Type 1 Diabetes management.2